The Intersection of anadas annabis Experiment & orporate ...
Lessons from Pharma for the Medical Cannabis Industry · 2019. 8. 8. · |12| Source: IMAR report...
Transcript of Lessons from Pharma for the Medical Cannabis Industry · 2019. 8. 8. · |12| Source: IMAR report...
|1|
Lessons from Pharma for the Medical Cannabis Industry
Ido Kanyon, CEO AusCann25.07.2019
|3|
Agenda
Medical Cannabis Opportunity
Medical Cannabis Fundamentals u
Market Access Drivers
Lessons from Pharma for the Medical Cannabis Industry
|4|
Cannabis
|5|
Cannabinoids
|6|
AdministrationDry flower Oil extract (vape)
Infused food Tablet / Capsule
Topical
Tincture
|7|
The endocannabinoid system is involved in regulating a variety of
physiological and cognitive processes including fertility, pregnancy, during
pre- and postnatal development, mood, appetite, sleep, memory,
pain-sensation, inflammation, and in mediating the pharmacological
effects of cannabis.
Endocannabinoid System (ECS)
|8| Source: 2014 American Academy of Neurology
Cannabis is mostly prescribed
to alleviate symptoms, reduce pain or improve
the patient quality of life
|9|
Example: How Multiple Sclerosis is treated Two main types of drug therapy are available:
Source: 2014 American Academy of Neurology: COMPLEMENTARY AND ALTERNATIVE MEDICINE FOR MULTIPLE SCLEROSIS, https://mswellington.org.nz/whatisms/what-are-the-symptoms-of-ms/
1) Disease-modifying therapiesthese reduce the number of relapses and may help slow disease progression
2) Symptomatic therapiesthese do not affect the course of the disease but help to relieve some of the symptoms
|10|
Medical Cannabis is prescribed to manage the
symptoms of a large array medical conditions
1 Qualifying medical conditions globally varies by country/state regulation Source: company research and https://www.pa.gov/guides/pennsylvania-medical-marijuana-program
▪ Amyotrophic lateral sclerosis▪ Autism▪ Arthritis▪ Cancer, including remission therapy▪ Crohn’s disease▪ Damage to the nervous tissue of the central nervous system
(brain-spinal cord) with objective neurological indication of intractable spasticity, and other associated neuropathies
▪ Dyskinetic and spastic movement disorders▪ Epilepsy▪ End of Life Care/Terminal illness▪ Glaucoma▪ HIV / AIDS▪ Huntington’s disease▪ Inflammatory bowel disease▪ Intractable seizures
▪ Insomnia ▪ Multiple sclerosis▪ Neurodegenerative diseases▪ Neuropathies▪ Opioid use disorder for which conventional therapeutic
interventions are contraindicated or ineffective, or for which adjunctive therapy is indicated in combination with primary therapeutic interventions
▪ Parkinson’s disease▪ Post-traumatic stress disorder▪ Severe chronic or intractable pain of neuropathic origin or
severe chronic or intractable pain▪ Sickle cell anemia▪ Spinal Cord Disease▪ End of Life Care ▪ Tourette syndrome
Partial list of qualifying medical conditions globally1:
|11|
Medical Cannabis Opportunity
Agenda
Medical Cannabis Fundamentals
u
Market Access Drivers
Lessons from Pharma for the Medical Cannabis Industry
|12| Source: IMARC report “Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023”
The global medical cannabis market is projected to grow from $11B in 2017 to $37B in 2023
Global Medical Cannabis MarketSales Value in US $Billion
Medical Cannabis Market by RegionSales Value in US $Billion
|13|
Medical Cannabis is a multibillion global business opportunity which is projected to grow in double-digit CAGR for the next coming years
The Medical Cannabis global opportunity
|13|Source: https://fortune.com/2018/12/20/cannabis-investments-2018/, https://www.bloomberg.com/press-releases/2019-06-27/medical-marijuana-market-worth-usd-25-25-billion-at-21-cagr-during-2018-2022-technavio, https://www.globenewswire.com/news-
release/2019/06/10/1866360/0/en/Medical-Marijuana-Market-to-Reach-a-Valuation-of-USD-54-677-1-million-through-2023-to-Grow-at-CAGR-of-34-0-Says-MRFR.html, https://www.marketwatch.com/press-release/at-244-cagr-medical-cannabis-market-size-will-reach-20200-
million-usd-by-2025-2019-06-18, https://www.globenewswire.com/news-release/2019/06/12/1867415/0/en/Medical-Cannabis-Market-will-grow-at-CAGR-of-29-3-to-hit-56-70-Bn-by-2026-Global-2019-Analysis-by-Growth-Size-Share-Price-and-Recent-Initiatives-Adroit-Market-
Research.html, https://bdsanalytics.com/new-report-global-legal-cannabis-markets-to-grow-36-in-2019-despite-2018-challenges-to-break-40-billion-by-2024/
|14|
Recreational Wellness Medical Pharmaceuticals
There are four main cannabis segments
|15|
With different regulations around the globe
Source: Marijuana Business Daily, 2018, Industry Insight: Countries to Watch, https://mjbizdaily.com/international-countries-to-watch-report/ (accessed May 2019)
|16|
Recent M&A / Business Development deals
|17|
And also one big Pharma
|18|
Market Access Drivers
Medical Cannabis Opportunity
Medical Cannabis Fundamentals
u
Lessons from Pharma for the Medical Cannabis Industry
Agenda
|19|
Regulators
Health Practitioners
Patients
Market access drivers
|20|
Market access for Cannabinoid-based medicines
Market access is challenged
by lack of standardisation
and medical acceptability
|21|
Regulated medicines are prescribed based on standardized science and validated clinical outcomes
▪ Cost of development: +200MUSD
▪ Exclusivity: 20 years/10 years from launch
▪ The regulatory framework together incentivise companiesto invest
▪ Robust economic engine
|22|
Lessons from Pharma for the Medical Cannabis Industry
Medical Cannabis Opportunity
Agenda
Medical Cannabis Fundamentals
u
Market Access Drivers
|23|
Lesson 1: Apply basic pharmaceuticals science
|24|
Lesson 2:Measure and publish safety and clinical outcome data
|27|
Lesson 3: Know the patient journey, know where to add value
Journey Phase
Origination
Awareness / Presentation
TreatmentFulfillment
Adherence
|28|
Lesson 4: Develop now considering how the treatment paradigm is likely to evolve in the next few years
|29|
Lessons from innovative Pharma
Lesson 5: Invest in your brand 70%Buy “a well known
trusted brand”
Say the most important driver for purchase is
effectiveness
91%
|30|
Apply basic pharmaceuticals science
Measure and publish safety and clinical outcome data
Know the patient journey, know where to add value
Develop now considering how the treatment paradigm is likely to evolve in the next few years
Invest in your brand
Lesson 1
Lesson 2
Lesson 3
Lesson 4
Lesson 5